



## Immune Design to Report First Quarter 2018 Financial Results and Provide Corporate Update

April 25, 2018

SEATTLE and SOUTH SAN FRANCISCO, Calif., April 25, 2018 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), an immunotherapy company focused on next-generation therapies in oncology, today announced that it will report first quarter 2018 financial results after the close of U.S. financial markets on Wednesday, May 2, 2018. Immune Design management will host a webcast conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on May 2, 2018 to discuss the financial results and provide a corporate update.

The live call may be accessed by dialing 844-266-9538 for domestic callers and 216-562-0391 for international callers. A live webcast of the call will be available online from the investor relations section of the company website at <http://ir.immunedesign.com/events.cfm> and will be archived there for 30 days. A telephone replay of the call will be available for five days by dialing 855-859-2056 for domestic callers or 404-537-3406 for international callers and entering the conference code: 1088768.

### About Immune Design

Immune Design is a late-stage immunotherapy company employing next-generation in vivo approaches to enable the body's immune system to fight disease. The company's technologies are engineered to activate the immune system's natural ability to generate and/or expand antigen-specific cytotoxic immune cells to fight cancer and other chronic diseases. CMB305 and G100, the leading product candidates with broad potential in oncology, are based on the company's two technology platforms that are potent stimulators of the immune system: ZVex<sup>®</sup> and GLAAS<sup>®</sup>. Both ZVex and GLAAS also have potential applications in infectious disease and allergy indications, which are being developed through ongoing pharmaceutical collaborations. Immune Design has offices in Seattle and South San Francisco. For more information, please visit [www.immunedesign.com](http://www.immunedesign.com).

### Media Contact

Julie Rathbun  
[julie.rathbun@immunedesign.com](mailto:julie.rathbun@immunedesign.com)  
206-769-9219

### Investor Contact

Sylvia Wheeler  
[Sylvia.wheeler@immunedesign.com](mailto:Sylvia.wheeler@immunedesign.com)

 [Primary Logo](#)

Source: Immune Design Corp.